If you have been reading about LC-MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-22. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Claudia Sheinbaum has pledged continuity with López Obrador's security strategy. She appointed Omar García Harfuch to the Secretariat of Security and Civilian Protection (SSPC). Under her administration, the SSPC's powers were expanded through legislation that facilitated closer collaboration with the Attorney General's Office, and greater intelligence gathering and sharing across government agencies. Her government also led targeted operations against cartel infighting, and a greater use of surveillance technology. Nemesio Oseguera Cervantes, the leader of the Jalisco New Generation Cartel, was killed by Mexican Army during the 2026 Jalisco operation on February 22, triggering widespread retaliatory violence and travel disruptions as the 2026 Mexico cartel unrest as due to the absence of leadership and ability of hardliners to push the state to a brink.
The styrene monomer (from which polystyrene is made) is "reasonably anticipated to be a human carcinogen". Styrene is "generally found in such low levels in consumer products that risks aren't substantial". Polystyrene which is used for food contact may not contain more than 1% (0.5% for fatty foods) of styrene by weight. Styrene oligomers in polystyrene containers used for food packaging have been found to migrate into the food. Another Japanese study conducted on wild-type and AhR-null mice found that the styrene trimer, which the authors detected in cooked polystyrene container-packed instant foods, may increase thyroid hormone levels. Whether polystyrene can be microwaved with food is controversial. Some containers may be safely used in a microwave, but only if labeled as such. Some sources suggest that foods containing carotene (vitamin A) or cooking oils must be avoided. Because of the pervasive use of polystyrene, these serious health related issues remain topical.
Unlike tramadol, it has only weak effects on the reuptake of serotonin and is a significantly more potent opioid with no known active metabolites. The potency of tapentadol is somewhere between that of tramadol and morphine, with an analgesic efficacy comparable to that of oxycodone despite a lower incidence of side effects. The CDC Opioid Guidelines Calculator estimates a conversion rate of 50mg of tapentadol equaling 10 mg of oral oxycodone in terms of opioid receptor activation. In the late 1980s, Grünenthal developed tapentadol to improve on tramadol, which they had created in 1962. Their goal was to design a molecule that minimized serotonin activity, strongly activated the μ-opioid receptor, inhibited norepinephrine reuptake, and worked without metabolic activation. The result was tapentadol. Due to the high risk of addiction, substance misuse, and dependence, tapentadol is a Schedule II controlled substance in the United States, a Schedule 8 controlled drug in Australia, and a Class A controlled substance in the United Kingdom.
=== Economics === The cost of alteplase in the United States increased by 111% between 2005 and 2014, despite there being no proportional increase in the costs of other prescription drugs. However, alteplase continues to be cost-effective.
Sources: en.wikipedia.org
== June 2, 1915 (Wednesday) == Second Battle of Artois — The French bombarded German defenses around Neuville-Saint-Vaast, France for three days before launching an attack. Shabin-Karahisar uprising — An Armenian militia of 250 began a month-long resistance against the Ottoman Empire in response to the Armenian genocide using a fort in the Giresun Province of Turkey. Ceylon Governor Robert Chalmers declared martial law in the colony (now Sri Lanka) after violent unrest between Muslim and Buddhist broke out in Kandy and spread to other towns and cities. The Imperial German Army established the 83rd and 84th Infantry Divisions. Born: Walter Tetley, American voice actor, best known as the voice of "Sherman" in the TV cartoon Mr. Peabody; as Walter Campbell Tetzlaff, in New York City, United States (d. 1975) Lester del Rey, American science fiction writer and publisher, editor with wife Judy-Lynn del Rey of Del Rey Books; as Leonard Knapp, in Saratoga Township, Winona County, Minnesota, United States (d. 1993) Li Lili, Chinese actress, known for film roles in Little Toys and The Big Road; as Qian Zhenzhen, in Beijing, Republic of China (present-day China) (d. 2005) Died: George Randell, 84, Australian politician, Member of the Western Australian Legislative Council from 1873 to 1875 and 1880 to 1890 (b. 1830) Dave Orr, 55, American baseball player, first baseman for various teams including the New York Metropolitans and the Brooklyn Bridegrooms from 1883 to 1890 (b. 1859)
On 17 May 2005, the committee held a hearing on allegations that Galloway received illicit payments from the Iraqi government through the Oil-for-Food Program. Attending Galloway's oral testimony and questioning him were two of the 13 committee members: the chair (Coleman) and the ranking Democrat (Carl Levin). On arriving in the US, Galloway told Reuters: "I have no expectation of justice from a group of Christian fundamentalist and Zionist activists." He described Coleman as a "pro-war, neocon hawk and the lickspittle of George W. Bush", who, he said, sought vengeance against anyone who did not support the war in Iraq. In his testimony, Galloway made the following statements in response to the allegations against him:
Hypnale hypnale is a venomous pit viper species endemic to India and Sri Lanka. Common names include the hump-nosed viper, Merrem's hump-nosed viper hump-nosed pit viper, and Oriental hump-nosed viper. No subspecies are currently recognized.
annealing The hybridization of two single-stranded nucleic acid molecules containing complementary sequences, creating a double-stranded molecule with paired nucleobases. The term is used in particular to describe steps in laboratory techniques such as polymerase chain reaction, where double-stranded DNA molecules are repeatedly denatured into single strands by heating and then exposed to cooler temperatures, causing the strands to reassociate with each other or with complementary primers. The exact temperature at which annealing occurs is strongly influenced by the length and specific sequence of the individual strands.
== See also == 3A (disambiguation) A3 (disambiguation) AA (disambiguation) AAAA (disambiguation) All pages with titles beginning with AAA All pages with titles containing AAA Aaahh!!! Real Monsters American Academy of Arts and Sciences (AAA&S) The Frank Zappa aaa•fnr•aaa Birthday Bundle, a 2008 digital download; AAAFNRAAA stands for "Anything Anytime Anywhere for No Reason At All, Again"
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.